Kodiak Sciences (NYSE:KOD) Sets New 1-Year High at $15.24

Kodiak Sciences Inc. (NYSE:KOD)’s stock price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $15.24 and last traded at $15.24, with a volume of 14689 shares traded. The stock had previously closed at $14.05.

KOD has been the subject of a number of research analyst reports. Chardan Capital restated a “buy” rating and set a $22.50 price objective on shares of Kodiak Sciences in a report on Thursday, June 13th. Zacks Investment Research cut Kodiak Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Kodiak Sciences currently has a consensus rating of “Buy” and an average price target of $17.50.

The firm’s 50-day simple moving average is $11.76 and its 200 day simple moving average is $9.84.

Kodiak Sciences (NYSE:KOD) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02).

A number of institutional investors and hedge funds have recently made changes to their positions in KOD. Deutsche Bank AG bought a new stake in shares of Kodiak Sciences in the fourth quarter worth $87,000. SG Americas Securities LLC bought a new stake in shares of Kodiak Sciences in the first quarter worth $66,000. Hillsdale Investment Management Inc. bought a new stake in shares of Kodiak Sciences in the second quarter worth $99,000. Summit Trail Advisors LLC bought a new stake in shares of Kodiak Sciences in the second quarter worth $211,000. Finally, Marshall Wace LLP bought a new stake in shares of Kodiak Sciences in the first quarter worth $258,000.

About Kodiak Sciences (NYSE:KOD)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.

Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.